Tag: Cardiovascular
PharmaSignal — Cardiovascular
Bayer wins MHRA approval for Kerendia in heart failure
PharmaTimes
New authorisation offers additional option for patients with lvef 40%
ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH
Pharmaceutical Technology
New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Pharmaceutical Technology
Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.
ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
Pharmaceutical Technology
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit
Pharmaceutical Technology
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarke
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
BioSpace
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
One in four diabetics has undiagnosed heart failure; study
Pharmaphorum
A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.
Immutrin raises $87M to advance drug for progressive heart disease
BioPharma Dive
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.